Importance: Identifying risk factors for radiationinduced optic neuropathy (RION) could promote a more conservative approach to radiation treatment planning in vulnerable patients.
INTRODUCTION
Radiation-induced optic neuropathy (RION) is a rare complication after external beam radiation therapy (EBRT) in which exposure of the anterior visual pathway to radiation results in acute, painless vision loss in one or both eyes months to years after treatment. 1 Radiation-induced ischaemic necrosis from free radical damage to the vascular endothelium has been theorized as the pathogenesis of RION. The severity of visual impairment ranges from subclinical changes in visual evoked potentials 2 to complete blindness. In many cases, visual function progressively deteriorates soon after the initial development of RION. While this disease-course suggests a possible treatment window, no interventions have definitely demonstrated efficacy stabilizing or reversing the visual decline. 1 Maximum radiation dose to the anterior visual pathway has been established as a significant determinant for the development of RION. 1, 3, 4 The anterior visual pathway has been shown to tolerate no greater than 50 Gy of cumulative radiation in fractions less than 2 Gy, with the incidence of RION increasing markedly at higher levels. [5] [6] [7] [8] [9] The incidence of RION following radiation treatment of head and neck or skull-base tumours has been quoted as ranging from 0% for <50Gy to 16% for >70Gy. 10 Current EBRT treatment planning protocols limit maximum point-doses to the optic pathway to 54-55 Gy in 1.8-2 Gy fractions to minimize this complication. 11 While previous studies have been instrumental in defining dose tolerance thresholds, fewer have investigated patient-associated systemic or demographic risk factors for developing RION. Those that do consider patient-associated attributes have been descriptive case reports, case series and reviews. These have described potentially predisposing factors for RION according to plausible pathogenic mechanisms.
3,12-14 Demizu et al. found a significant association for diabetes mellitus. 15 Deng et al. suggested that compression of the optic nerve by tumour may sensitize the visual pathway to radiation injury. 16 Guy et al. reported adjuvant chemotherapy as a potential risk factor. 17 Gragoudas et al. argue that risk may be enhanced by underlying vascular disorders, 18 and therefore that hypertension, hyperlipidaemia and smoking status may prove significant. Multiple authors indicate that age may play a role. 4, 19, 20 However, given the low incidence of RION under current EBRT planning protocols, a systematic analysis of these risk factors has remained elusive.
Identifying risk factors for developing RION could inform EBRT planning, monitoring and follow-up for high-risk patients. This would allow for a more complete discussion with the patient, modification of such risk factors, reconsideration of EBRT dose constraints to the optic apparatus and more aggressive neuro-ophthalmologic and neuroradiologic screening after EBRT to help mitigate the incidence and impact of this debilitating outcome.
A case-control study is an ideal method to identify risk factors which may be causally related to a specific outcome. We therefore performed a casecontrol study to identify potential patient-associated risk factors for RION. Cases (n = 14) with a neuroophthalmologic diagnosis of RION were compared against controls (n = 31) who had experienced maximum point doses to the optic pathway within an equivalent range but did not develop RION. The groups' characteristics and treatment parameters were interrogated by univariate analysis for predisposing attributes in an attempt to identify significant attributes associated with the development of RION.
METHODS
Cases were retrospectively identified from a singlecentre, neuro-ophthalmology database. All External beam radiation therapy planning records, which contoured the optic apparatus, were available for eight of the cases (57%). Radiation therapy (RT) planning records which did not specifically contour the optic apparatus but did report overall radiation doses to the affected area were available for the remaining five cases. A range of values for the maximum radiation doses to the affected optic nerves was extracted from radiation treatment planning records. This range (4479-6320 cGy) sets the upper and lower bounds for radiation exposure to the optic nerves in selected controls.
Controls were retrospectively selected from a single-centre, radiation oncology database. Criteria included RT for intracranial or skull-base tumours with radiation exposure to optic apparatus and at least 3 years of follow-up and no mention of vision loss prior to or following radiation therapy. A total of 31 controls were matched based exclusively upon total radiation to the optic apparatus. By matching controls and cases based on radiation dosage, which is widely reported in the literature as an independent risk factor for the development of RION, this study design attempts to identify other patient-specific factors predisposing to RION.
Variables of interest including race, age, gender, presence of diabetes mellitus, hypertension or hyperlipidaemia, smoking status, adjuvant chemotherapy or surgery and radiological evidence of tumour impingement on the optic apparatus were assessed by thorough chart review. There were no selection criteria regarding tumour type. There was no analysis of radiation dose as this was selected as matching criteria on the basis of the already widely reported significance of radiation dose as a significant factor for the development of RION. 1, 3, 4 For categorical variables, the control group and case group were compared with chi-squared or Fisher's exact tests as appropriate. For continuous variables, difference in the mean of the two groups was compared with t-tests or Kruskal-Wallis tests as appropriate. Absent matched pairing necessary for conditional logistic regression, a logistic regression model was used for univariate analyses of predictors for RION. Significance was defined as a P-value <0.05. Statistical analyses were performed with SAS version 9.3 (SAS Institute, Cary, NC, USA). All statistical tests were two-sided.
RESULTS

Patient characteristics
The relevant demographic and medical characteristics of cases and controls are summarized in Table 1 . The case group included 14 patients with a neuroophthalmologic diagnosis of RION. The median age of patients in the case group was 58 (5-82). There were 9 men and 5 women. A diversity of tumours was represented, unified by the diagnosis of RION.
Of these tumours, eight (57%) demonstrated radiological evidence of impingement on the optic apparatus either by mass effect, abutment, ensheathment or perineural invasion. In total, 3 patients (21%) had diabetes mellitus, 9 patients (64%) had hypertension, 5 patients (36%) had hyperlipidaemia and 3 patients (21%) had ever smoked tobacco. Regarding adjuvant therapies, 9 patients (64%) had surgery prior to RT, and 4 patients (29%) had concurrent chemotherapy.
Cases in this study commonly presented complaining of 'blurry vision' in the weeks prior to neuro-ophthalmologic evaluation. The mean latency period from last radiation treatment session to diagnosis of RION was 360 days (191-969 days).
Best corrected visual acuity at the time of diagnosis ranged from 20/25 to hand motion and progressed to no light perception in the most severe instances. Magnetic resonance imaging at diagnosis most commonly showed focal enhancement on T2 weighted images with increased fluid attenuation inversion recovery (FLAIR) signal in the affected optic nerves or chiasm. Patients in the control group were selected on the basis of having experienced maximum point doses to the optic pathway in an equivalent range as patients in the case group.
Cases and controls underwent EBRT, primarily intensity-modulated radiation therapy, which delivers radiation beams along multiple arcs with the shape and intensity of each beam designed to conform the dose around critical structures such as the optic nerve, thereby maximizing radiation delivery to the tumour while minimizing delivery to adjacent tissues. The radiation doses and dose volumes for treatments and controls are summarized in Table 2 . As per the defined selection criteria, the values of maximum point dose to the optic nerve between cases and controls are closely approximated.
Univariate analysis
Controlling for maximum radiation dose to the optic apparatus, no significant associations between any attributes of interest and an outcome of RION were found (Fig. 1, Table 3 ). No significant associations were found for established vascular risk factors including age, hypertension, hyperlipidaemia, diabetes mellitus or smoking status. No significant association was found for adjuvant therapies including chemotherapy or surgery. No significant association was found for radiological evidence of tumour impingement on the optic apparatus. Of note, vascular risk factors such as hyperlipidaemia, diabetes, older age and hypertension were associated with higher, albeit non-significant, odd ratios for RION. There being no significant differences in univariate analysis, a multivarite model was not applied.
DISCUSSION
Researchers have previously analysed the radiationassociated predictive factors for developing RION and found that radiation dosage is the most significant determinant for the incidence of RION. The risk increases with increasing radiation dose from 0% for <50Gy to upwards of 16% for >70Gy. 10, 19 An analysis of 273 patients receiving EBRT with curative intent for head and neck tumours and had radiation fields that included the optic nerve and/or chiasm found that the incidence of RION was 9%. 12 A retrospective study of 219 patients receiving radiation therapy for cancers of the paranasal sinuses and nasal cavity found no cases of RION when the total dose was under 50 Gy and calculated the 10-year actuarial risk for RION as 5% for doses of 50-60 Gy and 30% for doses of 61-78 Gy. 22 An additional study of 215 optic nerves in 131 patients found no risk of RION for doses less than or equal to 59 Gy. 19 For EBRT doses >60Gy, the risk of RION may increase with increasing dose per fraction. 19 In this study, patients were treated with standard fractionated EBRT where treatment was delivered in 1.8-2 Gy per fraction. Hyperfractionation delivers more than one fraction per day but at lower dose per fraction, such as 1.2 Gy twice per day. Previous studies have suggested that hyperfractionation may reduce the risk of RION by using lower dose per fraction. 12, 19 What literature has considered patient-associated predictive factors (i.e. patient demographics and comorbidities) is largely case-based. Bhandare, 12 Demizu 15 and Parsons 19 identified potential risk factors by isolating a rare few cases from prospective cohorts of hundreds receiving EBRT. Schreiber 14 and Girkin 21 suggest potential risk factors from retrospective case reports of individual patients.
Controlling for the significance of radiation dose by selecting the control subjects according to radiation exposures analogous to the case group, this study sought to analyse patient-associated predictive factors for developing RION independent of radiation dosage. In the univariate analysis, no significant associations with patient-specific or vascular factors were found.
RION is a form of late-delayed radiation-induced brain injury presenting greater than 6 months after radiotherapy. The associated white matter necrosis and vascular abnormalities seen on histopathology have variously been attributed to vascular endothelial injury or a reduction in the proliferating capacity of glial cells. 23 Neither explanation completely accounts for all clinical and experimental data, and so late delayed radiation induced injury may represent a complex interaction among multiple cell types. 24 Previously reported risk factors are consistent with the theorized pathogenesis of RION as a radiationinduced endotheliopathy. 12, 15, 18, 19 Similarly, this study found vascular risk factors including hyperlipidaemia, diabetes, older age and hypertension to be associated with higher odd ratios for RION. However, no association was significant. The absence of significant findings in this regard is perhaps attributable to the limited sample size and merits further investigation.
Adjuvant chemotherapy has been theorized by others to increase the risk of RION. 25, 26 While no association was found in this study, the particular This study sought to explore additional factors predisposing to RION in groups that otherwise received identical radiation with the premise that some factors other than radiation dosage must be contributory. Finding no such additional risk factor, these results support literature that strongly suggests that the primary risk factor for developing RION is radiation dosage and that additional patient-specific and vascular risk factors play a comparably minor role.
The significance of the findings in this preliminary study is constrained by the small sample size. The non-significant trend towards increased odds ratios for various cardiovascular risk factors may suggest that the study was not sufficiently powered. Indeed, for proportions for the female gender between the cases and controls (rounded to 0.35 and 0.60), the study would need n = 62 per group to have 80% power; for age ≤60, (rounded to 0.50 and 0.40) the study would need n = 388 per group to have 80% power.
A multi-site study would allow the researchers to more readily find significant associations and to interrogate multi-factorial predispositions, but such a study would be challenging given the rarity of the condition. A case-control study is the first step in trying to identify potential risk factors for RION. Future case-control studies could include pooled data from multiple institutions, allowing for a larger cohort of cases and controls, which might detect a diseaseeffect for some of these variables.
The retrospective nature of the study imposes limitations. The majority of cases did not have preoperative neuro-ophthalmalogic examinations, and so the degree of visual decline from baseline was not able to be assessed. Controls received no neuroophthalmologic evaluation, so the possibility of sub-clinical or incipient RION was not excluded from that group, despite setting inclusion criteria at greater than 3 years with no reported visual decline.
Reasoning from the proposed pathogenesis of RION as vascular endothelial or microglial injury, various treatments have been proposed. Systemic corticosteroids or intraocular corticosteroids, systemic anticoagulants, angiotensin converting enzyme inhibitors, hyperbaric oxygen and systemic or intraocular anti vascular endothelial growth factor have all been implemented with mixed results as reported in small case series and animal studies 27 ; however, no treatment to date has been definitely demonstrated to halt or reverse vision loss from RION.
Identifying risk factors for RION could promote a more conservative approach to radiation treatment planning in vulnerable patients. Three-dimensional conformal intensity-modulated radiotherapy could be used to reduce fraction size and minimize radiation dose to the optics for these high-risk patients. Pre-treatment and post-treatment ophthalmologic examination could identify incipient or subclinical cases with the potential to intervene earlier in the disease course. However, given the current ineffectiveness of present interventions, screening for at-risk patients promises the best potential to prevent vision loss from RION.
